Mersana Therapeutics - MRSN Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRSN shares.
View MRSN analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued twelve-month price targets for Mersana Therapeutics' shares. Their MRSN share price forecasts range from $10.00 to $20.00. On average, they predict the company's stock price to reach $14.71 in the next year. This suggests a possible upside of 256.3% from the stock's current price.
View analysts price targets for MRSN or view top-rated stocks among Wall Street analysts.

Mersana Therapeutics' stock was trading at $5.86 at the start of the year. Since then, MRSN shares have decreased by 29.5% and is now trading at $4.13.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our MRSN earnings forecast.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. The business earned $14.69 million during the quarter, compared to the consensus estimate of $27.85 million. Mersana Therapeutics had a negative trailing twelve-month return on equity of 178.80% and a negative net margin of 768.26%.

ETFs with the largest weight of Mersana Therapeutics (NASDAQ:MRSN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS).

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.67%), Marshall Wace LLP (2.53%), Braidwell LP (1.87%), Morgan Stanley (1.76%), Geode Capital Management LLC (1.71%) and Silverarc Capital Management LLC (1.14%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell, Timothy B Lowinger and Tushar Misra.
View institutional ownership trends.

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRSN stock can currently be purchased for approximately $4.13.

Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $446.16 million and generates $26.58 million in revenue each year. The company earns $-204,210,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.

The company employs 169 workers across the globe.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at ir@mersana.com.